Description

Montaro (Tirzepatide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use:

Not studied in patients with history of pancreatitis.
Not indicated for type 1 diabetes mellitus.

Pharmacology: Tirzepatide is a dual GIP and GLP‑1 receptor agonist. It is a 39‑amino‑acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs half‑life. It enhances first‑ and second‑phase insulin secretion and reduces glucagon levels in a glucose‑dependent manner.

Dosage & Administration:

Route: Subcutaneous injection.
Starting dose: 2.5 mg once weekly (for initiation only, not for glycemic control).
After 4 weeks: Increase to 5 mg once weekly.
Further titration: Increase in 2.5 mg increments after ≥4 weeks on current dose.
Maximum dose: 15 mg once weekly.
Missed dose: Administer within 4 days; otherwise skip and resume regular schedule.
Injection sites: Abdomen, thigh, or upper arm (rotate sites).
Do not freeze, do not mix with other drug solutions, protect from light.

Drug Interactions:

Reduce dose of sulfonylureas or insulin to lower hypoglycemia risk.
May delay gastric emptying, affecting absorption of oral drugs.
Oral contraceptives: Advise non‑oral or barrier method for 4 weeks after initiation and dose escalation.

Contraindications:

Hypersensitivity to Tirzepatide or components.
Personal/family history of medullary thyroid carcinoma (MTC) or MEN 2.

Side Effects: Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain.

Pregnancy & Lactation: Use only if potential benefit outweighs risk. Consider maternal clinical needs and potential effects on breastfed infant.

Precautions & Warnings:

Counsel patients on risk of thyroid tumors (MTC).
Monitor for pancreatitis, renal function, gallbladder disease, and diabetic retinopathy progression.
Discontinue if hypersensitivity occurs.

Use in Special Populations: Safety not established in children <10 years.

Overdose Effects: Supportive treatment based on symptoms; half‑life ~5 days.

Storage Conditions: Store at 2–8 °C in refrigerator. Do not freeze. Protect from light. Keep out of reach of children. Dispense only on registered physician’s prescription.